We're excited to announce that Medical Oncologist Dr Devika Das is joining us direct from WCLC 2025 to share her perspectives on the latest data in oncogene-addicted non-small cell lung cancer (NSCLC).

 

Dr Das is expected to review data from the following studies: 

  • Global TRUST-II: Updated efficacy and safety of taletrectinib in patients with ROS1+ NSCLC: The Global TRUST-II Study. Liu G, et al. Abstract MA02.02, WCLC 2025
  • SHERLOCK: Primary endpoint results from SHERLOCK: a phase 2 trial of sotorasib, bevacizumab and chemotherapy in advanced KRAS G12C NSCLC. Lee C. K, et al. Abstract OA03.04, WCLC 2025
  • REZILIENT1: Zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior amivantamab. Piotrowska Z, et al. Abstract MA08.02, WCLC 2025
  • Beamion LUNG-1: Zongertinib in patients with previously treated HER2-mutant NSCLC and brain metastases at baseline: Beamion LUNG-1. Ruiter G, et al. Abstract PT2.12.03, WCLC 2025
  • SOHO-01: Factors associated with clinical outcomes in patients with HER2-mutant NSCLC treated with sevabertinib (BAY 2927088). Le X, et al. Abstract P3.12.41, WCLC 2025

 

How will these developments impact the management of oncogene-addicted NSCLC? Check back soon to find out!

Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2-directed NSCLC

I am a board-certified hematologist and medical oncologist at UF Health, with 12 years of experience in academia and community oncology practice. It is my goal to apply both research and science toward providing equitable lung cancer care. I believe in providing the highest quality of care for patients-like I would want for myself and my loved ones.

 

I previously served as the section chief of oncology at the Birmingham VA Medical Center. I was also principal investigator for the lung precision oncology programme for veterans and served as the site director for the state veterans’ lung cancer screening program, along with other leadership roles.

 

I have experience as a medical educator, having served as a fellowship site director and associate fellowship program director, among other roles in health care education.

 

My research interests include designing and implementing high-quality clinical trials that are equitable and patient-centric, with a focus on enrolling those who are historically underrepresented in medicine.

 

Most recently, I was medical director for solid tumor oncology trials with Parexel and am currently an associate professor of medicine, disease group lead for thoracic oncology, and division director of quality and safety at the University of Florida in Gainesville. In this role, I focus on delivering the highest-quality clinical trials in lung cancer and enhancing the implementation of the lung cancer screening programme.

Dr Devika Das has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Boehringer Ingelheim

Programme summary
  • clock Duration 1 MIN
  • clock Language(s) flag
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Understanding the BRAFV600E testing and treatment landscapes in NSCLC

Two perspectives, one aim: A pathologist and a medical oncologist in discussion

Experts
Assoc. Prof. Umberto Malapelle, Prof. Nicolas Girard
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
animated-video Animated Video
Oncology 
Managing ADC toxicities in HER2+ metastatic breast cancer

Spotlight on nausea and vomiting

Experts
Dr Sara Tolaney
Endorsed by
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Aug 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
Oncology 
The latest developments in BRAF-mutant and MSI-H mCRC

Expert insights on recent clinical and real-world data

Experts
Prof. Chiara Cremolini
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
publication Scientific Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.